

# NeuroNEXT Network

## Standard Operating Procedure (SOP)




### Study Closeout Visits

Version 3.0


SOP NN SS 405

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

<p><b>Signature and Date:</b></p> <p>DocuSigned by Christopher Coffey</p> <p>   I approve this document 15-Feb-2023   8:20:56 AM PST</p> <p>15-Feb-2023</p> <p>C68AC8DD80334CF982AED1200765F147</p>
<p><b>Name and Title:</b> Christopher S. Coffey, PhD (DCC Principal Investigator)</p>
<p><b>Signature and Date:</b></p> <p>DocuSigned by Merit Cudkowicz</p> <p>   I approve this document 17-Feb-2023   1:53:14 AM EST</p> <p>17-Feb-2023</p> <p>9F8FE4180E504C6AB0A67B835E80C644</p>
<p><b>Name and Title:</b> Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)</p>
<p><b>Signature and Date:</b></p> <p>DocuSigned by Marianne Chase</p> <p>   I approve this document 15-Feb-2023   8:53:08 PM EST</p> <p>15-Feb-2023</p> <p>58FE690F6BCA4F2390E3DA15BCE3F578</p>
<p><b>Name and Title:</b> Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)</p>

**Signature and Date:**

DocuSigned by DIXIE ECKLUND  
 | I approve this document  
15-Feb-2023 | 10:58:09 AM PST  
7006AF622EFC40B6A067A08EC02591B6

15-Feb-2023

**Name and Title:** Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

**Signature and Date:**

DocuSigned by Stacey Grabert  
 | I approve this document  
22-Feb-2023 | 11:25:25 AM EST  
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

**Name and Title:** Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

**Signature and Date:**

DocuSigned by Joan Ohayon  
 | I approve this document  
15-Feb-2023 | 9:05:17 AM PST  
72C6AAFD8CC4485582ACA0700072901A

15-Feb-2023

**Name and Title:** Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

## **NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR STUDY CLOSEOUT VISITS**

### **1. POLICY**

The study closeout visit is intended to bring the study to a close at a NeuroNEXT clinical study site (CSS). The closeout visit is conducted according to the study monitoring plan and is scheduled after all obtainable visits for study subjects at the CSS have been completed and all data have been entered.

The term “study closeout visit” applies to all types of study closeout visits (on-site, regulatory only, remote) and all activities (pre-visit, during the visit, and post-visit) that are conducted by the NeuroNEXT Data Coordinating Center (DCC) and/or the Clinical Coordinating Center (CCC) until the study has been closed out at a CSS and with the Single Institutional Review Board (SIRB) and local site IRBs, as applicable.

Closeout visit activities that are conducted by the CCC and/or the DCC include, but are not limited to:

- reviewing the contents of the Trial Master File, the Site Regulatory Binder, and CSS study files;
- verifying that required regulatory documents and study records are on file, organized, and stored in a secure location;
- verifying that all protocol deviations have been resolved and corrective actions have been implemented;
- reviewing regulatory requirements regarding records retention and SIRB reporting requirements with the investigator;
- reviewing remaining un-monitored clinical data and resolving remaining data issues (e.g. data queries);
- confirming the disposition of the investigational product/device, if applicable, and any other ancillary items used for the study;
- confirming that all subject laboratory specimens have been forwarded to the appropriate location;
- generating final closeout visit reports, following up on all observations until they are resolved, and transmitting copies of the completed reports to the CSS, the CCC or DCC (as applicable), and the PPI/Sponsor;
- verifying that all monitoring requirements set forth in the study monitoring plan have been completed;
- determining, at the request of the PPI/Sponsor, that the investigator’s obligations have been met and that all applicable study and regulatory requirements have been fulfilled.

The CCC may conduct a remote closeout of regulatory documents via email, teleconference or video conference. Depending on the study, a remote closeout of sites with limited enrollment or no unmonitored data since the last monitoring visit may be conducted by the DCC.

### **2. SCOPE**

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

### **3. ROLES AND RESPONSIBILITIES**

The NeuroNEXT DCC and the CCC are responsible for conducting closeout visit activities with participating CSS according to the study monitoring plan. Closeout activities may take place after the last subject at a CSS has completed the study and all data entry has been completed.

The responsibility to conduct any or all of these activities may be delegated at the discretion of the Sponsor to the DCC, the CCC, or to subcontractors (if applicable). Those individuals and entities also take on responsibility for

meeting regulatory requirements on behalf of the Sponsor, but the Sponsor has the ultimate responsibility and must therefore supervise those delegated activities effectively.

#### **4. APPLICABLE REGULATIONS AND GUIDELINES**

21 CFR 312.56	Review of Ongoing Investigations
21 CFR 312.59	Disposition of Unused Supply of Investigational Drug
21 CFR 312.60	General Responsibilities of Investigators
21 CFR 312.62	Investigator Recordkeeping and Record Retention
21 CFR 312.64	Investigator Reports
21 CFR 312.68	Inspection of Investigator's Records and Reports
ICH E6, 4.12	Premature Termination of a Trial
ICH E6, 4.13	Final Reports by Investigator
ICH E6, 5.18	Monitoring
ICH E6, 5.20	Noncompliance
ICH E6, 5.21	Premature Termination of a Trial
ICH E6, 5.22	Clinical Trial/Study Reports

#### **5. REFERENCES TO OTHER APPLICABLE SOPS**

NN GA 104	Conflict of Interest and Financial Disclosure Requirements for Clinical Study Sites
NN GA 107	Data Sharing
NN GA 109	Sharing Data with Industry Collaborators
NN RA 201	Regulatory Authority Submissions and FDA Contact
NN RA 202	Trial Master File Maintenance
NN RA 203	Site Regulatory File Maintenance
NN RA 205	Adverse Events: Sponsor Responsibilities
NN RA 206	Medical Monitoring and Safety Monitoring
NN SS 401	Site Selection and Qualification
NN SS 402	Site Initiation Visits and Site Training
NN SS 403	Routine Monitoring Visits
NN SS 404	Site Performance Monitoring
NN SS 406	Suspension or Early Termination of a Study or a Clinical Site
NN PM 501	Communication
NN PM 505	Investigational Product Management
NN PM 507	Study Closeout
NN SM 602	Single Institutional Review Board Reporting
NN SM 603	Subject Eligibility and Enrollment
NN CS 706	Retention and Protection of Electronic Records
NN DM 1001	Clinical Data Management
NN DM 1005	Data Collection and Data Handling

## 6. ATTACHMENTS AND REFERENCES

NN SS 405 - A Document History

## 7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

AE	Adverse Events
CCC	Clinical Coordinating Center at Massachusetts General Hospital
CRF	Case Report Forms that are completed for each study subject at the sites
CSS	Clinical Study Site
CSS PI	Clinical Study Site Principal Investigator
DCC	Data Coordinating Center at The University of Iowa
FDA	U.S. Food and Drug Administration
ICH	International Council for Harmonisation
IRB	Institutional Review Board
PPI	Protocol Principal Investigator
PSC	Protocol Steering Committee
RMF	Regulatory Master File
SIRB	Single Institutional Review Board

## 8. SPECIFIC PROCEDURES

Additional acronyms used in this section: BIO – DCC Biostatistics team; DM – DCC Data Management team; IT – DCC Information Technology team; PC – DCC Protocol Coordination team; PM – CCC Project Management team.

### A. Preparing for Study Closeout Visits

#	Who	Task	Attachment	Related SOP
1.	Study Team	Develop a closeout visit plan that includes steps necessary to complete study closure at all participating CSS, including a timeline.		
2.	DCC PC and/or CCC PM, or designee	Verify that all subject visits and follow-up visits at the CSS are complete.		
3.	CCC PM, DCC PC, and PPI/Sponsor	Determine whether an onsite or remote closeout of regulatory documents will be conducted at a CSS.		
4.	CCC PM and/or DCC PC, or designee	Review the relevant contents of the project and site files in the RMF, if applicable, prior to the closeout visit or teleconference/video conference. Note that for sites that did not enroll any subjects, closeout activities may be conducted via email without teleconference/video conference.		
5.	CCC PM	Review a final report of all regulatory documents that have been uploaded to the study website for reconciliation.		

#	Who	Task	Attachment	Related SOP
6.	DCC PC, CCC PM and PPI/Sponsor	Determine whether an onsite or remote closeout of site files and study data will be conducted at a CSS.		NN SS 403
7.	DCC PC or designee	Review closeout visit monitoring requirements in the study monitoring plan.		NN SS 403
8.	DCC PC, DM, BIO; CCC PM	Determine reports/data listings that are needed for the closeout visit.		NN SS 403
9.	DCC PC or designee	Review previous monitoring reports to assess the scope of study documentation that must be available for review.		NN SS 403
10.	DCC PC or designee	If applicable, review data report and data queries for unmonitored data that are expected per the study monitoring plan since the time of the last monitoring visit.		NN SS 403 NN DM 1005
11.	Study Team	Review data completeness reports to track missing data and incomplete forms until all are accounted for.		
12.	DCC PC and/or CCC PM, or designee	Verify that data entry for the site is complete.		
13.	DCC IT and PC or designee	Track and verify that all Data Change Requests are complete.		NN DM 1005
14.	DCC PC and/or CCC PM, or designee	Verify that all outstanding AEs and SAEs have been resolved according to the requirements described in the safety monitoring plan for the study.		NN RA 206 NN SM 602
15.	CCC PM and/or DCC PC, or designee	Verify that all protocol deviations have been resolved and corrective action plans have been accepted by the PPI/Sponsor or designee (if applicable to a study).		
16.	DCC PC and/or CCC PM, or designee	Contact the CSS PI and the CSS Coordinator to arrange onsite or remote closeout visit(s) within a specified time period after the last subject's participation has concluded (if applicable).		NN PM 501
17.	DCC PC and/or CCC PM, or designee	For remote closeout visits, provide instructions to the CSS for teleconferencing or video conferencing (if necessary).		
18.	DCC PC and/or CCC PM, or designee	Confirm date and logistics of the closeout visit(s) with the CSS PI and the CSS Coordinator in writing.		NN PM 501
19.	DCC PC or designee	Inform the Study Team of the closeout visit date(s).		

#	Who	Task	Attachment	Related SOP
20.	DCC PC and/or CCC PM, or designee	Remote closeout will be considered for CSS with limited enrollment or with limited data to be reviewed. If closeout at a CSS is to be conducted remotely by central review, contact the site and request that copies of completed paper CRFs and source documentation for all subjects be uploaded to a secure platform for the DCC to review according to the provisions in the study monitoring plan.		NN PM 507
21.	DCC PC and/or CCC PM, or designee	Review the paper CRFs against data listings to ensure that data have been entered correctly, and that there are no missing data.		NN PM 507

## B. Conducting a Study Closeout Visit

*(For specific procedures related to closeout of regulatory documents, see Section 8.C)*

#	Who	Task	Attachment	Related SOP
1.	DCC PC and/or CCC PM, or designee	If a CSS has unmonitored data, conduct applicable tasks listed in NN SS 403 <i>Routine Monitoring Visits</i> .		NN SS 403
2.	DCC PC and/or CCC PM, or designee	Resolve any outstanding data corrections or issues with missing or incomplete CRFs.		NN PM 507 NN DM 1005
3.	DCC PC and/or CCC PM, or designee	Review the site's source documentation to ensure that it is current and complete.		NN RA 203
4.	DCC PC and/or CCC PM, or designee	If applicable, reconcile and collect all original investigational product accountability records.		NN PM 505
5.	DCC PC and/or CCC PM, or designee	If applicable, make copies of all investigational product accountability records for the study files at the CSS.		NN PM 505
6.	DCC PC and/or CCC PM, or designee	Verify the disposition of the investigational product/device.		NN PM 505
7.	CCC PM and/or DCC PC, or designee	Verify the disposition of study equipment, laboratory kits, and other study supplies (as applicable).		NN PM 505
8.	DCC PC and/or CCC PM, or designee	Verify that any laboratory specimens that remain at the CSS are handled or forwarded to the appropriate location according to the requirements of the study protocol and the informed consent document(s) signed by the study subjects.		

#	Who	Task	Attachment	Related SOP
9.	DCC PC and/or CCC PM, or designee	Conduct a closeout visit meeting with the CSS PI, CSS Study Coordinator, and any other applicable personnel.		
10.	DCC PC and/or CCC PM, or designee	Discuss with the investigator the requirements for maintaining clinical study documentation in a secure location after study completion for the period of time specified by FDA and/or the PPI/Sponsor.		NN RA 202 NN RA 203 NN CS 706 NN DM 1005
11.	DCC PC and/or CCC PM, or designee	Verify that the Delegation of Responsibility log has been updated with an end date for all personnel who were involved with study activities that will no longer occur.		NN RA 202 NN RA 203
12.	DCC PC and/or CCC PM, or designee	Obtain contact information for an individual at the site who may be contacted with questions if necessary after study closeout.		NN PM 501
13.	DCC PC and/or CCC PM, or designee	Verify that all monitoring requirements described in the study monitoring plan have been completed.		NN SS 403
14.	DCC PC and/or CCC PM, or designee	Document the study closeout visit, and collect the final monitoring log, if conducted on site.		NN SS 402 NN SS 403

### C. Conducting a Regulatory Document Closeout Visit

#	Who	Task	Attachment	Related SOP
1.	CCC PM and/or DCC PC, or designee	Review the contents of the Site Regulatory Binder with the CSS Coordinator and other CSS personnel, if applicable.		
2.	CCC PM and/or DCC PC, or designee	Confirm the long-term storage location(s) for the regulatory documents with the CSS.		NN RA 203
3.	CCC PM and/or DCC PC, or designee	Verify that the Delegation of Responsibility log has been updated with an end date for all applicable personnel.		NN RA 202 NN RA 203
4.	CCC PM and/or DCC PC, or designee	Verify that the site has completed all required regulatory activities.		
5.	CCC PM and/or DCC PC, or designee	Send a post-review report to the CSS PI, the CSS Coordinator, the PPI/Sponsor, and the DCC. The report details all required corrections to study regulatory documents and identifies any missing documents that must be obtained prior to study closeout.		



#### D. Post-visit Activities and Study Closeout Visit Report(s)

#	Who	Task	Attachment	Related SOP
1.	DCC PC and/or CCC PM, or designee	Instruct the CSS to transmit any required regulatory documents that were identified at the closeout visit to the CCC (as needed).		NN RA 202 NN RA 203 NN PM 501
2.	DCC PC and/or CCC PM, or designee	Complete study closeout report(s) for regulatory documents and site file/study data (as applicable), and transmit the report(s) to the CSS PI, the PPI/Sponsor, and the CCC or DCC (as applicable). <ul style="list-style-type: none"> <li>These reports summarize findings from the monitoring visit(s) and include instructions for study records retention. If applicable, include a list of clinical site responsibilities and deliverables prior to study closeout.</li> </ul>		NN SS 403
3.	DCC PC and/or CCC PM, or designee	Follow up on any issues discovered during the study closeout visit(s) and detailed in the study closeout visit report(s) until all are resolved.		NN SS 403 NN PM 507
4.	DCC PC	Verify that all outstanding corrections to the site data have been implemented through a post-complete change or a Data Change Request to the DCC.		NN PM 507 NN DM 1005
5.	DCC PC and/or CCC PM, or designee	Confirm that the CSS PI and/or the responsible leader of the Study Team at each CSS has reviewed and signed off on all study data that have been submitted for all subjects at the close of the study.		NN GA 107 NN GA 109 NN DM 1005
6.	CCC PM and/or DCC PC, or designee	Make the final determination that the investigator's obligations have been met and that all study and regulatory requirements have been fulfilled.		
7.	CCC PM or designee	Verify that the clinical site has updated the Delegation of Responsibility log to reflect the official date of SIRB closure as the end date for all active study personnel, request a copy for the CCC, and file the copy with the site regulatory documents.		
8.	CCC PM and SIRB Liaison	Complete closeout procedures with the SIRB.		
9.	DCC PC and/or CCC PM, or designee	Provide the study PPI/Sponsor with the final monitoring visit report(s).		
10.	CCC PM or designee	File the study closeout visit report(s) with the regulatory documents.		
11.	Study Team	Review and follow procedures described in SOP NN PM 507 <i>Study Closeout</i> .		NN PM 507

Certificate Of Completion

Envelope Id: EDB0DBE89047456CBCD5CFCBF2DEF31D Status: Completed
Subject: Complete with DocuSign: NN SS 405 Study Closeout Visits v3.0.docx
Source Envelope:
Document Pages: 9 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.123.188.5
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/15/2023 8:19:02 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey Signature Timestamp
christopher-coffey@uiowa.edu Christopher Coffey Sent: 2/15/2023 8:20:43 AM
Security Level: Email, Account Authentication Viewed: 2/15/2023 11:20:41 AM
(Required), Login with SSO Signed: 2/15/2023 11:20:58 AM

Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 11:20:41 AM
ID: c6c057e7-896d-4c4a-b941-f462e174db01

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication
(Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
15-Feb-2023 | 10:58:09 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/15/2023 8:20:44 AM
Viewed: 2/15/2023 1:56:48 PM
Signed: 2/15/2023 1:58:12 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 1:56:48 PM
ID: 33200a00-569f-4c71-bc32-6aef344719ac

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Joan Ohayon  
ohayonj@ninds.nih.gov  
Security Level: Email, Account Authentication (Required)

*Joan Ohayon*

Sent: 2/15/2023 8:20:46 AM  
Viewed: 2/15/2023 12:05:00 PM  
Signed: 2/15/2023 12:05:21 PM

Signature Adoption: Pre-selected Style  
Signature ID:  
72C6AAFD-8CC4-4855-82AC-A0700072901A  
Using IP Address: 156.40.137.188

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Accepted: 2/13/2023 2:03:22 PM  
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase  
MCHASE@mgh.harvard.edu  
Sr Director, Clinical Trial Operations  
Insight OBO The Massachusetts General Hospital  
Security Level: Email, Account Authentication (Required)

*Marianne Chase*


Sent: 2/15/2023 8:20:45 AM  
Viewed: 2/15/2023 8:51:53 PM  
Signed: 2/15/2023 8:53:20 PM

Signature Adoption: Pre-selected Style  
Signature ID:  
58FE690F-6BCA-4F23-90E3-DA15BCE3F578  
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

Merit Cudkowicz  
cudkowicz.merit@mgh.harvard.edu  
Chief of Neurology  
Security Level: Email, Account Authentication (Required), Logged in


DocuSigned by Merit Cudkowicz  
 I approve this document  
17-Feb-2023 | 1:53:14 AM EST  
9F8FE4180E504C6AB0A67B835E80C644

Sent: 2/15/2023 8:20:45 AM  
Viewed: 2/17/2023 1:53:05 AM  
Signed: 2/17/2023 1:53:16 AM

Signature Adoption: Pre-selected Style  
Signature ID:  
9F8FE418-0E50-4C6A-B0A6-7B835E80C644  
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Accepted: 2/17/2023 1:53:05 AM  
ID: b037cc06-ef40-4ca8-b143-ee85dc705dc4

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	  Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49  With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/15/2023 8:20:46 AM Viewed: 2/22/2023 11:25:14 AM Signed: 2/22/2023 11:25:28 AM
<b>Electronic Record and Signature Disclosure:</b> Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/15/2023 8:20:47 AM
Certified Delivered	Security Checked	2/22/2023 11:25:14 AM
Signing Complete	Security Checked	2/22/2023 11:25:28 AM
Completed	Security Checked	2/22/2023 11:25:28 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact Insight OBO The Massachusetts General Hospital:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu)

### **To advise Insight OBO The Massachusetts General Hospital of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from Insight OBO The Massachusetts General Hospital**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with Insight OBO The Massachusetts General Hospital**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.